News for CERS Stock

Cerus Corporation to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 Cerus Corporation Presents Clinical Data for INTERCEPT Blood System at the 35th Regional International Society of Blood Transfusion Congress in Milan Cerus Corporation Announces Multiple In-Country Regulatory Approvals for INT200 – Next-Generation INTERCEPT Illumination Device Cerus Corporation Announces First Quarter 2025 Financial Results Cerus Corporation to Release First Quarter 2025 Financial Results on May 1, 2025 Cerus Corporation Announces Receipt of CE Mark for Next-Generation INTERCEPT Illumination Device (INT200) Cerus Corporation Announces Full-Year and Fourth Quarter 2024 Financial Results Cerus Corporation to Participate in the TD Cowen 45th Annual Health Care Conference Cerus Corporation to Release Fourth Quarter and Full-Year 2024 Financial Results on February 20, 2025 Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2024 Product Revenue and Provides Business Update Cerus Corporation to Participate in Upcoming Investor Conferences Cerus Corporation Announces Third Quarter 2024 Financial Results Cerus Corporation to Release Third Quarter 2024 Financial Results on October 30, 2024 Cerus Corporation Announces Workshop and Abstracts at the 2024 AABB Annual Meeting Cerus Corporation Provides Updates on INTERCEPT Red Blood Cell Programs in the U.S. and Europe Cerus Corporation Announces Second Quarter 2024 Financial Results and Increases Full-Year 2024 Product Revenue Guidance Range Cerus Corporation to Release Second Quarter 2024 Financial Results on August 1, 2024 Cerus Corporation Announces Appointment of Dean Gregory to Board of Directors Cerus Corporation Announces Symposium and Abstracts at the 38th International Congress of the International Society of Blood Transfusion Cerus Corporation Celebrates World Blood Donor Day 2024 Cerus Corporation to Participate in 21st Annual Craig-Hallum Institutional Investor Conference Cerus Corporation Announces First Quarter 2024 Financial Results Cerus Corporation to Release First Quarter 2024 Financial Results on May 2, 2024 Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets – Doubling Previous Shelf Life Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients Cerus Corporation Announces Fourth Quarter and Full-Year 2023 Financial Results Cerus Corporation to Release Fourth Quarter and Full-Year 2023 Financial Results on March 5, 2024 Cerus Corporation to Participate in Upcoming Investor Conferences Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2023 Product Revenue and Provides Business Update Cerus Corporation to Participate in Upcoming Investor Conferences Cerus Corporation Announces Third Quarter 2023 Financial Results Bloodbuy Announces Agreement with Cerus Corporation to Offer Pathogen Reduced Cryoprecipitated Fibrinogen Complex on its Digital Marketplace Cerus Corporation to Release Third Quarter 2023 Financial Results on November 2, 2023 Cerus Corporation Announces Workshop and Abstracts at the 2023 AABB Annual Meeting Cerus Corporation Announces the Appointment of Alicia Goodman as New Chief Human Resources Officer Cerus Corporation to Participate in the 2023 Cantor Global Healthcare Conference Cerus Corporation Announces Second Quarter 2023 Financial Results Cerus Corporation to Release Second Quarter 2023 Financial Results on August 2, 2023 Cerus Corporation Announces Symposium and Abstracts at the 33rd Regional ISBT Congress Cerus Corporation Celebrates World Blood Donor Day 2023 Cerus Corporation Announces Follow-on Award of U.S. Department of Defense Funding for Development of Pathogen Reduced, Lyophilized Cryoprecipitate Cerus Corporation Announces First Quarter 2023 Financial Results Cerus Corporation to Release First Quarter 2023 Financial Results on May 4, 2023 Cerus Corporation Announces Record Fourth Quarter and Full-Year 2022 Financial Results Cerus Corporation to Release Fourth Quarter and Full Year 2022 Financial Results on February 28, 2023 Cerus Corporation to Participate in Upcoming Investor Conferences Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2022 Product Revenue and Provides Business Update Cerus Corporation to Participate in Upcoming Investor Conferences Cerus Corporation Announces Third Quarter Financial Results Cerus Corporation Announces Award of U.S. Department of Defense Funding for Development of Pathogen Reduced, Lyophilized Cryoprecipitate Cerus Corporation Announces Health Canada Approval for INTERCEPT Blood System for Platelets with Seven-Day Storage Cerus Corporation to Release Third Quarter 2022 Financial Results on November 3, 2022 Cerus Corporation Announces Workshop and Abstracts at the 2022 AABB Annual Meeting Cerus Corporation Acknowledges Growing Monkeypox Outbreak and Public Health Emergency Cerus Corporation Announces Another Record Quarter and Reiterates Full Year 2022 Product Revenue Guidance Range Cerus Corporation to Release Second Quarter 2022 Financial Results on August 4, 2022 Cerus Corporation Announces Appointment of Hua Shan, MD, PhD to Board of Directors Cerus Corporation Celebrates World Blood Donor Day 2022 Cerus Corporation Announces First Quarter 2022 Financial Results and Increases Full Year 2022 Product Revenue Guidance Range Cerus Corporation Announces New Manufacturing and Supply Agreement With Fresenius Kabi For INTERCEPT Blood System Sets Cerus Corporation Announces Multi-Year Contract for the INTERCEPT Blood System for Platelets with the American Red Cross Cerus Corporation to Release First Quarter 2022 Financial Results on May 5, 2022 Cerus Corporation to Participate at the Cowen 42nd Annual Health Care Conference Cerus Corporation Announces Record Fourth Quarter and Full-Year 2021 Financial Results Cerus Corporation to Release Fourth Quarter and Full-Year 2021 Financial Results on February 22, 2022 Cerus Corporation to Participate in Upcoming Virtual Investor Conferences Cerus Corporation Announces Record Preliminary Fourth Quarter and Full-Year 2021 Product Revenue and Provides Business Update Cerus Corporation to Participate in Stephens Annual Investment Conference Cerus Corporation to Participate in Stifel 2021 Virtual Healthcare Conference Cerus Corporation Announces Record Third Quarter 2021 Financial Results and Raises Full-Year Product Revenue Guidance Cerus Corporation to Release Third Quarter 2021 Financial Results on November 2, 2021 Cerus Corporation Applauds FDA Requirements Effective Today to Safeguard the U.S. Platelet Supply Cerus Corporation Announces INTERCEPT Fibrinogen Complex Customer Presentations at SABM Virtual Annual Meeting 2021 Cerus Corporation to Present at the 2021 Cantor Global Virtual Healthcare Conference Cerus Corporation Announces CMS Issuance of P-Codes for Hospital Outpatient Billing of INTERCEPT-Based Therapeutic Products Cerus Corporation Announces Appointment of Ann Lucena to Board of Directors Cerus Corporation Announces Record Second Quarter 2021 Financial Results and Raises Full Year Product Revenue Guidance Cerus Corporation Announces CMS Has Granted New Technology Add-On Payment for INTERCEPT Fibrinogen Complex Cerus Corporation to Release Second Quarter 2021 Financial Results on August 3, 2021 Cerus Corporation and the Swiss Red Cross Celebrate 10 Years of Routine Use of INTERCEPT Blood System for Platelets Cerus Announces Collaboration with LifeSouth Community Blood Centers to Manufacture INTERCEPT® Fibrinogen Complex Cerus Corporation Celebrates World Blood Donor Day 2021 Cerus Corporation Announces Contract with Canadian Blood Services for INTERCEPT Blood System for Platelets Cerus Corporation Announces First Quarter 2021 Financial Results and Raises Full Year Product Revenue Guidance Cerus Corporation to Release First Quarter 2021 Financial Results on May 4, 2021 Cerus Corporation to Participate in Jefferies Virtual Global Plasma Summit Cerus Corporation Announces Record Fourth Quarter and Full Year 2020 Financial Results Cerus Corporation and Shandong Zhongbaokang Medical Implements Partner to Establish Joint Venture in China Cerus Corporation to Release Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021 Cerus Corporation to Participate in Upcoming Virtual Investor Conferences Cerus Corporation Announces Preliminary Fourth Quarter and Full Year 2020 Product Revenue Cerus’ Distribution Partner, CEI, Announces Three-Year Tender Award with the Minas Gerais Hematology and Hemotherapy Center Foundation (HemoMinas) in Brazil for the INTERCEPT Blood System for Platelets Cerus Corporation Announces Presentation of Study Results with INTERCEPT-treated COVID-19 Convalescent Plasma at the American Society of Hematology Annual Meeting Cerus Corporation Announces FDA Approval for INTERCEPT Blood System for Cryoprecipitation Cerus Corporation to Participate in Upcoming Virtual Investor Conferences Cerus Corporation Announces Record Third Quarter 2020 Results Cerus Corporation to Release Third Quarter 2020 Financial Results on October 29, 2020 Cerus Corporation Announces Five-Year FDA Contract for the Development of Next Generation Pathogen Reduction Technology to Treat Whole Blood Cerus Corporation Announces Schedule of Presentations at the AABB 2020 Virtual Annual Meeting